[go: up one dir, main page]

WO2008052043A3 - Opioid receptor agonist fusion proteins - Google Patents

Opioid receptor agonist fusion proteins Download PDF

Info

Publication number
WO2008052043A3
WO2008052043A3 PCT/US2007/082363 US2007082363W WO2008052043A3 WO 2008052043 A3 WO2008052043 A3 WO 2008052043A3 US 2007082363 W US2007082363 W US 2007082363W WO 2008052043 A3 WO2008052043 A3 WO 2008052043A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor agonist
opioid receptor
fusion proteins
proteins
agonist fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/082363
Other languages
French (fr)
Other versions
WO2008052043A2 (en
WO2008052043A9 (en
Inventor
Craig A Rosen
Adam C Bell
Indrajit Sanyal
David Lafleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Biopharmaceuticals USA Inc
Original Assignee
Cogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cogenesys Inc filed Critical Cogenesys Inc
Publication of WO2008052043A2 publication Critical patent/WO2008052043A2/en
Publication of WO2008052043A9 publication Critical patent/WO2008052043A9/en
Publication of WO2008052043A3 publication Critical patent/WO2008052043A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are fusion proteins that include an opioid receptor agonist protein, or a fragment, variant, or an analog thereof fused to a serum protein. Suitable serum proteins for the fusion proteins in albumin, alpha- fetoprotein (AFP) and albumin- AFP hybrid proteins. The fusion proteins have opioid receptor agonist activity. Typically, the fusion proteins may exhibit extended or stabilized opioid receptor agonist activity in vivo or in vitro relative to an opioid receptor agonist that is not fused to the serum protein.
PCT/US2007/082363 2006-10-24 2007-10-24 Opioid receptor agonist fusion proteins Ceased WO2008052043A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85374606P 2006-10-24 2006-10-24
US60/853,746 2006-10-24

Publications (3)

Publication Number Publication Date
WO2008052043A2 WO2008052043A2 (en) 2008-05-02
WO2008052043A9 WO2008052043A9 (en) 2008-07-31
WO2008052043A3 true WO2008052043A3 (en) 2009-01-08

Family

ID=39325375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082363 Ceased WO2008052043A2 (en) 2006-10-24 2007-10-24 Opioid receptor agonist fusion proteins

Country Status (1)

Country Link
WO (1) WO2008052043A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
US12257229B2 (en) 2018-01-03 2025-03-25 Spitfire Pharma Llc Peptide pharmaceuticals for treatment of NASH and other disorders

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008297524A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of Thymopentin as a therapeutic agent
AU2008306192A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of leptin (22-56 ) as a therapeutic agent
WO2009040006A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Spantide for therapeutic uses
EP2476410A1 (en) * 2011-01-13 2012-07-18 Theralpha An analgesic peptide-containing composition for transbuccal administration
WO2012095523A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic composition for transbuccal administration
KR102365582B1 (en) 2012-11-20 2022-02-18 메더리스 다이어비티즈, 엘엘씨 Improved peptide pharmaceuticals for insulin resistance
EP4047023A1 (en) * 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
CN117180445A (en) 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 Improved peptide drugs against insulin resistance
RS61907B1 (en) 2015-04-06 2021-06-30 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
EP3592800A4 (en) * 2017-03-10 2021-01-06 Bolt Threads, Inc. Compositions and methods for producing high secreted yields of recombinant proteins
KR20250121449A (en) * 2017-03-10 2025-08-12 볼트 쓰레즈, 인크. Compositions and methods for producing high secreted yields of recombinant proteins
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
CN107964047B (en) * 2017-12-18 2018-11-02 哈尔滨工业大学 Chimeric peptide and its synthetic method based on Tyr-Pro-Trp-Phe-NH2 and neurotensin (8-13) and application
US12264329B1 (en) * 2024-06-10 2025-04-01 Wyvern Pharmaceuticals Inc. Composition for regulating production of fusion proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469631A (en) * 1980-03-10 1984-09-04 The Regents Of The University Of California Fusion peptides comprising an expressible bacterial gene and β-endorphin
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20030022308A1 (en) * 1992-01-31 2003-01-30 Aventis Behring L.L.C. Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
WO2005077042A2 (en) * 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469631A (en) * 1980-03-10 1984-09-04 The Regents Of The University Of California Fusion peptides comprising an expressible bacterial gene and β-endorphin
US20030022308A1 (en) * 1992-01-31 2003-01-30 Aventis Behring L.L.C. Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2005077042A2 (en) * 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAGGIO L L ET AL: "A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis", DIABETES, NEW YORK, NY, US, vol. 53, 1 September 2004 (2004-09-01), pages 2492 - 2500, XP003004469, ISSN: 0012-1797 *
HUGHES J ET AL: "Identification of two related pentapeptides from the brain with potent opiate agonist activity.", NATURE 18 DEC 1975, vol. 258, no. 5536, 18 December 1975 (1975-12-18), pages 577 - 580, XP009104778, ISSN: 0028-0836 *
KELLAM BARRIE ET AL: "Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 161, no. 1, 9 February 1998 (1998-02-09), pages 55 - 64, XP002492914, ISSN: 0378-5173 *
OSBORN B L ET AL: "Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-alpha Fusion Protein in Cynomolgus Monkeys", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, EXPERIMENTAL THERAPEUTICS, BALTIMORE, MD, vol. 303, no. 2, 1 January 2002 (2002-01-01), pages 540 - 548, XP003006693, ISSN: 0022-3565 *
SCHLECHTINGEN GEORG ET AL: "Structure-activity relationships of dynorphin a analogues modified in the address sequence.", JOURNAL OF MEDICINAL CHEMISTRY 22 MAY 2003, vol. 46, no. 11, 22 May 2003 (2003-05-22), pages 2104 - 2109, XP002492913, ISSN: 0022-2623 *
VARGA E V ET AL: "The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 50, no. 6, 1 December 1996 (1996-12-01), pages 1619 - 1624, XP009104735, ISSN: 0026-895X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257229B2 (en) 2018-01-03 2025-03-25 Spitfire Pharma Llc Peptide pharmaceuticals for treatment of NASH and other disorders
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists

Also Published As

Publication number Publication date
WO2008052043A2 (en) 2008-05-02
WO2008052043A9 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008052043A3 (en) Opioid receptor agonist fusion proteins
WO2009058957A3 (en) Intranasal administration of active agents to the central nervous system
WO2011035202A3 (en) Universal fibronectin type iii binding-domain libraries
IL176894A0 (en) Albumin fusion proteins
EP1924596A4 (en) Albumin fusion proteins
IL222924A0 (en) Albumin fusion proteins
EP2068905A4 (en) Albumin fusion proteins
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
HK1200842A1 (en) Proteins with improved half-life and other properties
CA2691692C (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2535351A3 (en) Dual specificity antibody fusions
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
ZA200810677B (en) Fusion proteins, uses thereof and processes for producing same
WO2007076032A3 (en) Compositions and methods for producing a composition
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
WO2006002161A3 (en) Modulators of odorant receptors
WO2010013012A3 (en) Hypothermia inducing polypeptides and uses thereof
ZA200801224B (en) Albumin fusion proteins
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2006054096A3 (en) Soluble bifunctional proteins
WO2006091824A3 (en) Peptides for detection of antibody to porcine reproductive respiratory syndrome virus
WO2007057778A3 (en) Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor
EP1929031A4 (en) In vitro protein synthesis systems for membrane proteins that include apolipoproteins and phospholipid-apolipoprotein particles
WO2006076742A3 (en) Methods and compositions for increasing membrane permeability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868556

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07868556

Country of ref document: EP

Kind code of ref document: A2